Geron Corporation (NASDAQ:GERN) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET
Company Participants
Dr. John Scarlett - Chairman, Chief Executive Officer
Dr. Andrew Grethlein - Executive Vice President, Chief Operating Officer
Dr. Faye Feller - Executive Vice President, Chief Medical Officer
Michelle Robertson - Executive Vice President, Chief Financial Officer.
Aron Feingold - Vice President of Investor Relations, Corporate Communication
Conference Call Participants
Tara Bancroft - TD Cowen
Carter Gould - Barclays
Stephen Willey - Stifel
Corinne Johnson - Goldman Sachs
Gil Blum - Needham & Company
Kalpit Patel - B. Reilly Securities
Operator
Hello! And welcome to the Geron Corporation Second Quarter 2024 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. [Operator Instructions].
I would now like to turn the conference over to Aron Feingold, Vice President of Investor Relations and Corporate Communication. You may begin.
Aron Feingold
Good morning, everyone. Welcome to the Geron Corporation second quarter 2024 earnings conference call. I am Aron Feingold, Geron's Vice President of Investor Relations and Corporate Communication.
I'm joined today by several members of Geron's management team. Dr. John Scarlett, Chairman and Chief Executive Officer; Dr. Andrew Grethlein, Executive Vice President and Chief Operating Officer; Dr. Faye Feller, Executive Vice President and Chief Medical Officer; and Michelle Robertson, Executive Vice President and Chief Financial Officer.
On today's call, Chip will start off with introductory remarks on commercial execution and value creation. Andy will provide a commercial and operations update. Faye will speak to medical and clinical updates, Michelle will provide a financial review, and Chip will close with some final remarks.
Before we begin, please note that during the course of this presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations, and other projections, including those relating to the launch, commercial opportunity, and therapeutic potential of RYTELO, anticipated clinical and commercial events and related timelines, the sufficiency of Geron's financial resources, and other statements that are not historical fact. Actual events or results could differ materially.
Therefore, I refer you to the discussion under the heading, Risk Factors, in Geron's most recent periodic report filed with the SEC, which identifies important factors that could cause actual results to differ materially from those contained in the forward-looking statements. Geron undertakes no duty or obligation to update our forward-looking statements.